These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35437301)

  • 1. Factors Associated with Non-Adherence for Prescribed Treatment in 201 Patients with Multidrug-Resistant and Rifampicin-Resistant Tuberculosis in Anhui Province, China.
    Zhu QQ; Wang J; Sam NB; Luo J; Liu J; Pan HF
    Med Sci Monit; 2022 Apr; 28():e935334. PubMed ID: 35437301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal Analysis of Prevalence and Risk Factors of Rifampicin-Resistant Tuberculosis in Zhejiang, China.
    Liu Z; Zhang M; Wang J; Chen S; Wu B; Zhou L; Pan A; Wang W; Wang X
    Biomed Res Int; 2020; 2020():3159482. PubMed ID: 32104686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
    Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
    J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.
    Bykov I; Dyachenko O; Ratmanov P; Liu H; Liang L; Wu Q
    BMC Infect Dis; 2022 Jul; 22(1):612. PubMed ID: 35831812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia.
    Desissa F; Workineh T; Beyene T
    BMC Public Health; 2018 Apr; 18(1):422. PubMed ID: 29606112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China.
    Wang K; Chen S; Wang X; Zhong J; Wang X; Huai P; Wu L; Wang L; Jiang S; Li J; Peng Y; Yao H; Ma W
    Microb Drug Resist; 2014 Aug; 20(4):294-300. PubMed ID: 24328894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
    Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES
    BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.
    Xia H; Zheng Y; Liu D; Wang S; He W; Zhao B; Song Y; Ou X; Zhou Y; van den Hof S; Cobelens F; Zhao Y
    Microbiol Spectr; 2021 Dec; 9(3):e0040921. PubMed ID: 34851179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for diagnosis and treatment delay among patients with multidrug-resistant tuberculosis in Hunan Province, China.
    Akalu TY; Clements ACA; Gebreyohannes EA; Xu Z; Bai L; Alene KA
    BMC Infect Dis; 2024 Feb; 24(1):159. PubMed ID: 38308252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State.
    Mulu W; Mekonnen D; Yimer M; Admassu A; Abera B
    Afr Health Sci; 2015 Jun; 15(2):368-77. PubMed ID: 26124781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with unfavorable treatment outcomes in patients with rifampicin-resistant tuberculosis in Colombia 2013-2015: A retrospective cohort study.
    Chaves-Torres NM; Fadul S; Patiño J; Netto E
    PLoS One; 2021; 16(4):e0249565. PubMed ID: 33852619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
    Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
    BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting time to treatment initiation after diagnosis for multidrug-resistant/rifampicin-resistant tuberculosis patients: A mixed-methods study in Jakarta, Indonesia.
    Silitonga P; Jiang W; Wyatt S; Burhan E; Kes EFM; Long Q
    Trop Med Int Health; 2023 Jan; 28(1):43-52. PubMed ID: 36477995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends and characteristics of drug-resistant tuberculosis in rural Shandong, China.
    Tao NN; He XC; Zhang XX; Liu Y; Yu CB; Li HC
    Int J Infect Dis; 2017 Dec; 65():8-14. PubMed ID: 28958922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China.
    Liang L; Wu Q; Gao L; Hao Y; Liu C; Xie Y; Sun H; Yan X; Li F; Li H; Fang H; Ning N; Cui Y; Han L
    Thorax; 2012 Jul; 67(7):632-8. PubMed ID: 22403070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and risk factors of anxiety and depression in patients with multi-drug/rifampicin-resistant tuberculosis.
    Dan-Ni Z; Guang-Min Z; Yu-Hua D; Ying L; Ting W; Yuan-Yuan C; Yu-Hong X; Xin-Cai X
    Front Public Health; 2024; 12():1372389. PubMed ID: 38601494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
    Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
    Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.